.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,964,572

« Back to Dashboard

Details for Patent: 7,964,572

Title:High affinity nucleic acid ligands of complement system proteins
Abstract: Methods are described for the identification and preparation of high-affinity Nucleic Acid Ligands to Complement System Proteins. Methods are described for the identification and preparation of high affinity Nucleic Acid Ligands to Complement System Proteins C1q, C3 and C5. Included in the invention are specific RNA ligands to C1q, C3 and C5 identified by the SELEX method.
Inventor(s): Biesecker; Gregory (Boulder, CO), Gold; Larry (Boulder, CO)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Filing Date:Nov 28, 2005
Application Number:11/288,622
Claims:1. A method for inhibiting inflammation or membrane attack vascular disease comprising administering to a patient in need thereof a pharmaceutically effective amount of a nucleic acid ligand of a C5 complement system protein wherein said nucleic acid ligand comprises the polynucleotide of SEQ ID NO: 194, 195, or 196.

2. The method of claim 1 wherein said nucleic acid ligand comprises the polynucleotide of SEQ ID NO: 196.

3. The method of claim 1 wherein said nucleic acid ligand comprises the polynucleotide of SEQ ID NO: 194.

4. The method of claim 1 wherein said nucleic acid ligand comprises the polynucleotide of SEQ ID NO: 195.

5. A method for inhibiting activation of a membrane attack pathway in vivo, the method comprising administering to a patient in need thereof a pharmaceutically effective amount of a nucleic acid ligand comprising the polynucleotide of SEQ ID NO: 194, 195 or 196.

6. The method of claim 5 wherein said nucleic acid ligand comprises the polynucleotide of SEQ ID NO: 194.

7. The method of claim 5 wherein said nucleic acid ligand comprises the polynucleotide of SEQ ID NO: 195.

8. The method of claim 5 wherein said nucleic acid ligand comprises the polynucleotide of SEQ ID NO: 196.

9. A method for inhibiting C5 complement activation, the method comprising administering to a patient in need thereof a pharmaceutically effective amount of a nucleic acid ligand comprising the polynucleotide of SEQ ID NO: 194, 195 or 196.

10. The method of claim 9 wherein said nucleic acid ligand comprises the polynucleotide of SEQ ID NO: 194.

11. The method of claim 9 wherein said nucleic acid ligand comprises the polynucleotide of SEQ ID NO: 195.

12. The method of claim 9 wherein said nucleic acid ligand comprises the polynucleotide of SEQ ID NO: 196.

13. The method of claim 1, wherein the ligand inhibits activation of the inflammation or the membrane attack pathway.

14. The method of claim 1, wherein the ligand is connected via a linker to a non-immunogenic, high molecular weight compound.

15. The method of claim 5, wherein the ligand is connected via a linker to a non-immunogenic, high molecular weight compound.

16. The method of claim 9, wherein the ligand is connected via a linker to a non-immunogenic, high molecular weight compound.

17. The method of claim 1, wherein inflammation is inhibited.

18. The method of claim 1, wherein membrane attack vascular disease is inhibited.

19. A method for inhibiting hemolysis, renal injury in autoimmune glomerulonephritis or leukocyte activation during extracorporeal circulation, comprising administering to a patient in need thereof a pharmaceutically effective amount of a nucleic acid ligand comprising the polynucleotide of SEQ ID NO: 194, 195 or 196.

20. The method of claim 19 wherein said nucleic acid ligand comprises the polynucleotide of SEQ ID NO: 194.

21. The method of claim 19 wherein said nucleic acid ligand comprises the polynucleotide of SEQ ID NO: 195.

22. The method of claim 19 wherein said nucleic acid ligand comprises the polynucleotide of SEQ ID NO: 196.

23. The method of claim 19, wherein the ligand is connected via a linker to a non-immunogenic, high molecular weight compound.

24. The method of claim 14, wherein the non-immunogenic, high molecular weight compound is polyethylene glycol.

25. The method of claim 15, wherein the non-immunogenic, high molecular weight compound is polyethylene glycol.

26. The method of claim 16, wherein the non-immunogenic, high molecular weight compound is polyethylene glycol.

27. The method of claim 23, wherein the non-immunogenic, high molecular weight compound is polyethylene glycol.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc